Hier meine Diskussionsgrundlage
Topics:
(sure, there are some aspects under disclosure)
* Alderley ‚take over‘
How could you convince Management of ‚old‘ Chesapeake to make a 45m CAD sharebased deal for a cultural transition?
·What was proved at your lab tests of metates samples?
·What are the other assumptions except for the functionality of the oxidation process?
·How much was the recovery of small scale test labs?
·Is the recovery of silver as good supposed as for gold?
·Who is responsible in your Team for the development of oxidation technology/chemistry?
* License
·What are the annual fees?
·What is the progress provided by Alderley?
·What are the terms to be fulfilled?
·Why are there no other licensees?
·Is everything database merged with the Licensor? What is the difference in knowledge?
* Metates
·Is most of the ore refractory?
·Is it a horizontale deposit?
·How deep is the ore drilled?
·How deep is the ‚highgrade‘?
·Is the ‚highgrade‘ one concentraed core? (supposed stripp off)
·Why are the old autoclave capex/cash costs per tpd far under average in terms of peers?
·Would green gold be essential for permitting? (water rights, energy)
·Do you think at a stable POG of 2300 at a supposed of an IRR of 30% aftertax there is a chance of going into production with autoclave?
·You mentioned an average oxidation leaching recovery of 75% at the crux investor interview.
Could it really be cheaper in terms of cash costs than autoclave with 90%+ recovery? DFS2016 cash costs of about 750usd net gold doesn't look that bad.
·Do you update the autoclave part of the DFS beside the integrated new scoping study für heap leach?
·What newsflow could investors assume in the next 12-24 months?
peter